Home Ingredients Nicotinamide Riboside
EnergyMetabolic HealthCognitiveLongevity

Nicotinamide Riboside

Evidence Level
Strong
4 Clinical Trials
7 Documented Benefits
4/5 Evidence Score

Nicotinamide Riboside (NR) is a vitamin B3 derivative that serves as a precursor to NAD+ (nicotinamide adenine dinucleotide), the central coenzyme in cellular energy metabolism. NAD+ levels decline with aging — by age 50, NAD+ levels are roughly half of youthful levels — and this decline is associated with reduced mitochondrial function, sirtuin activity, and DNA repair capacity. NR supplementation efficiently raises blood NAD+ levels in clinical trials (typically 40-50% increase at standard doses). Most published clinical evidence uses Niagen® from ChromaDex — essentially the only commercially viable branded NR form with manufacturing capability at scale. Competing NAD+ precursor NMN exists but is in regulatory limbo in the US. The honest framing: well-evidenced blood NAD+ elevation in humans; longevity claims rest more on mechanism than long-term clinical trials in healthy adults; expensive supplementation with uncertain real-world health span benefits at current evidence levels.

Studied Dose Standard dose: 250-1,000 mg/day NR. Most clinical trials use 300-600 mg/day. Take with or without food. Effects on blood NAD+ levels appear within 2-4 weeks; downstream health benefits less reliably established.
Active Compound Nicotinamide Riboside — a vitamin B3 derivative and direct precursor to NAD+. Niagen® (ChromaDex) is the most-studied branded form and dominates commercial supply.

Benefits

Documented blood NAD+ elevation

Multiple clinical trials show NR supplementation raises blood NAD+ levels 40-50% at standard doses within 2-4 weeks. The biomarker effect is well-established and reproducible — addresses the age-related NAD+ decline that's been hypothesized to contribute to multiple aging-related conditions.

Supported by Trial 1

Mitochondrial function support (preliminary)

Cellular and animal studies show NR supports mitochondrial biogenesis, function, and resistance to oxidative damage through NAD+-dependent sirtuin and PARP enzyme activation. Human evidence for functional mitochondrial improvements is emerging but less robust than the biomarker NAD+ elevation.

Supported by Trial 1, Trial 3

Cardiovascular biomarkers in older adults

Clinical trials in older adults show NR supplementation may reduce blood pressure and improve arterial stiffness in those with stage 1 hypertension. Effects are modest but consistent across small trials; cardiovascular outcome trials are still needed.

Supported by Trial 2

Possible cognitive aging support

Animal studies suggest NR supports neuronal function and may protect against cognitive aging. Human clinical evidence for cognitive function improvement is preliminary; not yet validated as a cognitive enhancer in healthy adults or as a treatment for mild cognitive impairment.

Supported by Trial 3, Trial 1

Sirtuin and PARP enzyme support

NAD+ is required for sirtuin enzymes (involved in longevity pathways) and PARP enzymes (DNA repair). NR supplementation supports these enzyme activities at the biochemical level. Mechanism aligns with longevity-research positioning, though human longevity outcomes remain unproven.

Supported by Trial 1, Trial 4

Honest counter-evidence on clinical benefits

While NR reliably elevates blood NAD+, translating this to clear clinical benefits in healthy adults has been more elusive. Many specific health benefit claims rest on mechanism rather than well-validated clinical trials. The 'longevity' positioning is partially speculative based on mouse models.

Supported by Trial 1, Trial 3

Niagen® dominance and generic alternatives

Niagen® (ChromaDex) is essentially the only commercially viable NR with reliable manufacturing. Generic alternatives exist but quality and stability vary significantly. Most clinical evidence uses Niagen® specifically; cost premium is partly justified by manufacturing complexity.

Supported by Trial 1, Trial 2

Mechanism of action

1

CD73-mediated cellular uptake

NR enters cells via nucleoside transporters and is phosphorylated by NR kinases (NRK1/2) to form NMN, which is then adenylylated to NAD+. This pathway bypasses the rate-limiting NAMPT step that limits nicotinamide (niacinamide) conversion — making NR one of the most efficient oral NAD+ precursors.

2

Sirtuin activation (SIRT1–7)

Elevated NAD+ activates all seven sirtuin deacylases simultaneously. SIRT1 and SIRT3 are particularly important — SIRT1 drives mitochondrial biogenesis via PGC-1α deacetylation, while SIRT3 protects mitochondria from oxidative damage and regulates metabolic enzymes.

3

PARP-1 and DNA repair

PARP-1 consumes NAD+ during DNA strand break repair. Chronically elevated PARP-1 activity (from accumulating DNA damage with age) depletes cellular NAD+, creating a vicious cycle. NR restores NAD+ substrate availability for both PARP-1 and sirtuins — two competing yet complementary longevity mechanisms.

Clinical trials

1
Niagen® NR Dose-Escalation in Healthy Adults — First Human Trial

First-in-human dose-escalation study of nicotinamide riboside (Niagen®) at 100, 300, 1,000 mg/day for 8 weeks in 12 healthy adults. Outcomes: whole-blood NAD+, NAD+ metabolome. (Nat Commun)

12 healthy adults. 8-week dose-escalation.

All doses dose-dependently elevated whole-blood NAD+. 300 mg/day: ~50% increase; 1,000 mg/day: ~140%. Foundational human PK trial confirming oral NR raises NAD+ levels. Critical caveat: NAD+ elevation is a biomarker — does not directly establish clinical benefits. The translation from elevated NAD+ to meaningful clinical outcomes (longevity, healthspan) remains an active research question with limited definitive human data.

2
NR for Arterial Stiffness — University of Colorado Clinical Trial

Randomized, double-blind, crossover trial of NR (1,000 mg/day) vs placebo in 30 adults aged 55-79 with elevated SBP for 6 weeks each. (Nat Commun)

30 adults aged 55-79 with elevated BP.

NR reduced aortic pulse wave velocity (~9%) and systolic BP (~8 mmHg) vs placebo in those with stage 1 hypertension. Modest cardiovascular signal in this small trial. Independent replication needed.

3
NR for NAFLD — Clinical Trial

Clinical trial of NR (1,000 mg/day) vs placebo in overweight/obese adults with NAFLD for 12 weeks.

Overweight/obese NAFLD adults.

NR elevated liver NAD+, modestly reduced hepatic lipid content, improved markers of mitochondrial function. Note: NAFLD/MASLD landscape has been transformed by GLP-1 agonists (semaglutide, tirzepatide) and resmetirom (Rezdiffra® — FDA-approved 2024). NR adjunctive at most.

4
Niagen® NR Long-Term Safety — 8-Week Trial

GRAS-affirmed safety trial examining NR supplementation (250-2,000 mg/day) in healthy adults for 8 weeks. (Sci Rep)

Healthy adults. Safety study.

No serious adverse effects at any dose up to 2,000 mg/day. No changes in liver enzymes, kidney function, lipids. Generally well-tolerated. Established NR safety profile for supplemental use.

Side effects and drug interactions

Common Potential side effects

Generally very well tolerated across all studied doses up to 2,000 mg/day
Mild nausea, flushing, or GI discomfort reported by small percentage of users — significantly less flushing than niacin
Headache reported rarely at higher doses (>1,000 mg/day)

Important Drug interactions

No established clinically significant drug interactions at standard doses
Alcohol — ethanol metabolism consumes NAD+; NR may partially offset alcohol-induced NAD+ depletion
Chemotherapy — NAD+ supports DNA repair mechanisms; theoretical concern about protecting tumor cells; consult oncologist
Isoniazid (TB drug) — competes with NAD+ precursor metabolism; monitor if combining

Featured in these supplement guides

Energy & Fatigue→

More Energy Ingredients

Energy
Caffeine
Caffeine, a natural stimulant found in coffee, tea, and other plants, is commonly suppleme…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Energy
Iron
Iron is an essential mineral best known for its central role in making hemoglobin, the pro…
Hydration
Glucose / Dextrose
Glucose (also called dextrose in its pure crystalline form) is the body's primary fuel sug…

Explore Other Ingredients

Energy
NMN (Nicotinamide Mononucleotide)
NMN (nicotinamide mononucleotide) is a precursor that the body uses to make NAD+, a coenzy…
Energy
SalidroPure™ (Pure Salidroside)
SalidroPure™ is NNB Nutrition's precision-fermented pure salidroside — the primary bioacti…
Cardiovascular
Resveratrol
Resveratrol is a polyphenol antioxidant found in grape skins, red wine, and Japanese knotw…

Related articles from our blog

📝 Article
🧬 The Longevity Blueprint: Supplements That May Help You Live Better, Longer
We all want to live a long life—but not just longer . We want more years with energy, sharp thinking, and physical vital…
June 06, 2025
📝 Article
NMN, NAD+, and NR: Do Anti-Aging Supplements Actually Work?
Few corners of the supplement world are hyped quite like NAD+ boosters. NMN and NR are sold as the closest thing to an a…

Frequently asked questions about Nicotinamide Riboside

How much nicotinamide riboside should I take?

Common doses are 250 to 500 mg per day, the amounts used in most human studies (the branded form Niagen is frequently used at 300 mg). Some people use up to 1,000 mg, though more is not proven to be better.

What is nicotinamide riboside used for?

NR is a form of vitamin B3 and a precursor to NAD+, a coenzyme central to energy metabolism and cellular repair that declines with age. It is studied for healthy aging, energy, and metabolic and cardiovascular support.

NR or NMN, which should I choose?

Both raise NAD+ and are closely related. NR (nicotinamide riboside) has more published human trials and an established branded ingredient, while NMN is one step closer to NAD+ in the pathway. For most people the practical difference is small.

Is nicotinamide riboside safe?

Human studies show NR is generally well tolerated at common doses, reliably raising NAD+ levels. Long-term outcome data is still developing. Check with your doctor if pregnant, breastfeeding, or undergoing cancer treatment.

What is Nicotinamide Riboside?

Nicotinamide Riboside (NR) is a vitamin B3 derivative that serves as a precursor to NAD+ (nicotinamide adenine dinucleotide), the central coenzyme in cellular energy metabolism.

What is the recommended dosage of Nicotinamide Riboside?

The clinically studied dose is Standard dose: 250-1,000 mg/day NR. Most clinical trials use 300-600 mg/day. Take with or without food. Effects on blood NAD+ levels appear within 2-4 weeks; downstream health benefits less reliably established. Always follow the product label and check with a healthcare provider for personal advice.

Is Nicotinamide Riboside safe, and does it have side effects?

For most healthy adults, Nicotinamide Riboside is well tolerated at studied doses. Reported effects can include: Generally very well tolerated across all studied doses up to 2,000 mg/day Mild nausea, flushing, or GI discomfort reported by small percentage of users — significantly less flushing than niacin It may also interact with some medications. Nicotinamide Riboside is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Nicotinamide Riboside interact with any medications?

Possible interactions include: No established clinically significant drug interactions at standard doses Alcohol — ethanol metabolism consumes NAD+; NR may partially offset alcohol-induced NAD+ depletion If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Nicotinamide Riboside?

NutraSmarts rates the evidence for Nicotinamide Riboside as Strong (4 out of 5). It is backed by 4 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. doi: 10.1038/ncomms12948.PubMedUsed to support: First human pharmacokinetic study demonstrating that oral nicotinamide riboside is bioavailable and dose-dependently raises blood NAD+ in humans. Establishes the core proven effect: NR boosts NAD+. No clinical outcome was tested.
  2. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. doi: 10.1038/s41467-018-03421-7.PubMedUsed to support: Randomized crossover RCT: NR 1000 mg/d for 6 weeks was well tolerated and raised NAD+ about 60% in healthy older adults. A blood-pressure/arterial-stiffness improvement was seen only as a non-significant trend (suggestive in those with elevated baseline). Supports NAD+ elevation and safety; clinical benefit not demonstrated.
  3. Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28(7):1717-1728.e6. doi: 10.1016/j.celrep.2019.07.043.PubMedUsed to support: Randomized placebo-controlled crossover trial in aged men: NR 1000 mg/d raised the muscle NAD+ metabolome and shifted inflammatory signatures, but produced NO clear improvement in muscle function, strength, or mitochondrial bioenergetics. Reinforces 'raises NAD+ but functional benefit unproven.'
  4. Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019;9(1):9772. doi: 10.1038/s41598-019-46120-z.PubMedUsed to support: 8-week RCT in overweight adults: NR dose-dependently increased blood NAD+ (up to about 142% at 1000 mg/d) and was well tolerated with no flushing and an adverse-event rate like placebo. Confirms safety and NAD+ elevation; again no efficacy outcome established, consistent with 'NAD+ proven, clinical benefits unproven.'